TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Spinal Mepivicaine With Fentanyl for Outpatient Knee Arthroscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients having unilateral arthroscopic surgery of the knee;~2. ASA I-III status;~3. Age 18-80 years;~4. BMI\< 35.~Exclusion Criteria:~1. Patients who have previous history of hypersensitivity to local anesthetics or contraindications for spinal anesthesia (i.e. bleeding diathesis, coagulopathy);~2. Patients with radiating low back pain and neurological deficits in lower extremities;~3. Patients who are incapable of giving an informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Mepivicaine for spinal anesthesia
- 2 (Type: EXPERIMENTAL): Mepivacaine with Fentanyl for spinal anesthesia

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Open Label Extension Study in Participants With Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Have given written informed consent~* Women must not be pregnant, breastfeeding or be at risk to become pregnant during study participation~* Have participated in either Study H9B-MC-BCDG (NCT00689728) or Study H9B-MC-BCDH (NCT00785928)~Exclusion Criteria:~* Have had, during Study H9B-MC-BCDG (NCT00689728) or Study H9B-MC-BCDH (NCT00785928), any safety event, \[including having a recent, ongoing, or serious infection, a serious drug reaction, or any adverse event (AE) that caused discontinuation from treatment\] that in the opinion of the investigator poses an unacceptable risk to participation in the study.~* Have received, during Study H9B-MC-BCDG (NCT00689728) or Study H9B-MC-BCDH (NCT00785928), any drug not allowed by the study protocol including unapproved drugs, biologic disease-modifying anti-rheumatic drugs (DMARDs), or live vaccines.~* Enrollment in any other clinical trial involving off-label use of an investigational drug or device, or enrollment in any other type of medical research.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LY2127399 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Double-Blind, Placebo-Controlled Study to Evaluate 3 Doses of a Novel Tetracycline in the Treatment of Facial Acne Vulgaris

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* if women of child-bearing potential, have a negative urine pregnancy test~* Willing to use only a non-medicated cleanser and to refrain from use of any other acne medication, medicated cleanser, excessive sun exposure, and tanning booths for the duration of the study~* Male or female, 12-45 years of age with body weight between 52 and 88 kg~* Diagnosis of acne vulgaris with:~  20 to 50 inflammatory lesions (papules, pustules, and nodules) 30 to 100 noninflammatory lesions (open and closed comedones)~* No more than 2 nodules on the face~* Investigator's Global Assessment (IGA) score of moderate (3) to severe (4)~Exclusion Criteria:~* Dermatological condition of face or facial hair that could interfere with clinical evaluations subjects who have used the following medications (topical refers only to the facial area) will not be eligible:~Within 1 week prior to randomization:~* Medicated facial cleansers~* Topical acne treatments (other than those listed below)~Within 4 weeks prior to randomization:~* Topical retinoids~* Topical anti-inflammatories and corticosteroids~* Systemic antibiotics~* Systemic acne treatments~Within 12 weeks prior to randomization:~* Systemic retinoids~* Systemic corticosteroids~* Pseudomembranous colitis or antibiotic-associated colitis~* Hepatitis, liver damage or renal impairment

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- P005672-HCl approximately 0.75 mg/kg/day (Type: EXPERIMENTAL): One P005672-HCl 50 mg capsule and one Placebo capsule, oral administration, once daily for 12 weeks
- P005672-HCl approximately 1.5 mg/kg/day (Type: EXPERIMENTAL): Two P005672-HCl 50mg capsules, oral administration, once daily for 12 weeks
- P005672-HCl approximately 3.0 mg/kg/day (Type: EXPERIMENTAL): Two P005672-HCl 100mg capsules, oral administration, once daily for 12 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Two Placebo capsules matching P005672-HCl, oral administration, once daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Donor Simvastatin Treatment in Organ Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria for a donor:~* Heart transplant donor~* Age 18-60 years~* Previously healthy~* No cholesterol medication~* Normal ECHO with LVEF \>45%, normal right ventricle and normal coronary angiography~* PiO2/FiO2 \> 40kPA, normal chest radiograph and normal bronchoscopy in lung donors~Exclusion Criteria for the heart/lung donor:~* Severe left ventricular hypertrophy \> 14 mm~* High dose of inotropes (dopamine or dobutamine \> 20ug/kg/min or norepinephrine \>0.2 ug/kg/min) at the time of procurement~* Donor outside of the study country Finland~Inclusion criteria for a transplant recipient:~* Age between 18-70 for heart transplant recipients~* Male or female~* Listed for heart, lung, kidney, or liver transplantation~Exclusive Criteria for the recipient~* systemic sepsis~* a positive cross match

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Simvastatin 80 mg group (Type: ACTIVE_COMPARATOR): The transplant recipients who have received an organ from donors treated with simvastatin 80 mg.
- Control Rx (Type: EXPERIMENTAL): The transplant recipients who have received an organ from non-treated donors.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Multicenter, Randomized, Open Label Study to Evaluate the Lipid Lowering Efficacy and Safety of Vytorin® 10/20 vs. Atorvastatin 10mg in Hypercholesterolemia Patients With Metabolic Syndrome in Korea (0653A-129)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of the metabolic syndrome according to 2005 American Heart Association/National Heart, Lung and Blood Institute (AHA/NHLBI) scientific statement~* No history of diabetes and 100 \<=LDL-C \<=250 mg/dl~Exclusion Criteria:~* Myocardial Infarction, coronary artery bypass surgery, or angioplasty within 3 months~* Congestive heart failure defined by New York Heart Association (NYHA) class III or IV~* Uncontrolled endocrine or metabolic disease known to influence serum lipids or lipoproteins~* Uncontrolled hypertension~* Unstable angina

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Vytorin® (Type: EXPERIMENTAL): simvastatin (+) ezetimibe 10/20 mg (Vytorin®) ; tablet, once daily, 8 Weeks
- atorvastatin (Type: ACTIVE_COMPARATOR): atorvastatin 10 mg; tablet, once daily, 8 Weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Genetically Informed Smoking Cessation Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult (≥21 years of age), seeking treatment for smoking cessation.~2. Able to speak English,~3. Active smoking (Cigarettes Per Day (CPD) ≥5), and exhaled Carbon Monoxide (CO) ≥8 ppm~4. Agree to participate in this randomized smoking cessation trial with follow up assessments up to 12 months.~Exclusion Criteria:~1. Pregnancy or breast feeding,~2. Active use or recent use (\< or equal to 1 month) of medication or e-cigarettes for nicotine dependence/smoking cessation, or use of e-cigarettes for more than 9 days in the prior month,~3. Allergy to nicotine patch, lozenge, or varenicline,~4. Unwillingness to prevent pregnancy during the medication phase and 1 month afterwards (women only),~5. Significant cardiac conditions (myocardial infarction, unstable angina, coronary angioplasty, cardiac bypass) or serious arrhythmia in past 6 months,~6. Current heavy alcohol consumption (≥6 drinks/day, 6 days/week),~7. Active psychosis or poorly controlled depression within the past 6 months,~8. Any prior suicide attempt or suicidal ideation within the past 6 months,~9. End stage renal disease with hemodialysis.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Combination NRT and Counseling (Type: ACTIVE_COMPARATOR): Combination Nicotine replacement therapy (cNRT) (patch and lozenge) and smoking cessation counseling will be provided to participants. Lozenges will be given for 12 weeks with a 1 week pre-quit titration and patch for 12 weeks. Seven smoking counseling sessions will be given during treatment.
- Varenicline (Chantix) and Counseling (Type: ACTIVE_COMPARATOR): Varenicline (pill) and smoking cessation counseling will be provided to participants for 12 weeks with 1 week pre-quit titration. Seven smoking cessation counseling sessions will be given during treatment.
- Placebo Medicine and Counseling (Type: PLACEBO_COMPARATOR): Placebo pill and smoking cessation counseling will be provided to participants for 12 weeks with 1 week pre-quit titration. Placebo lozenges will be given for 12 weeks with a 1 week pre-quit titration and patch for 12 weeks. Seven smoking counseling sessions will be given during treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Anti-Helicobacter Pylori Antibodies (IgG) in Serum of Women With Unexplained Infertility

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. regular cycles.~2. normal thyroid function, prolactin and androgen levels.~3. normal semen analysis of the partner.~4. normal hysterosalpingography.~5. normal transvaginal ultrasound examination.~Exclusion Criteria:~1. possible uterine malformations or pathologies.~2. presence of infections, including hepatitis, human immunodeﬁciency virus (HIV), TORCH, Chlamydia trachomatis and Mycoplasma.~3. presence of anti-sperm antibodies in serum.~4. Male factor infertility.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- unexplained infertility patients (Type: None): 44 patients diagnosed to have unexplained infertility
- Fertile women (Type: None): 44 fertile women

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study of Switching From One Pain Medication to Another (Opioid Rotation)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age of 18 to no upper limit~* Chronic pain of nociceptive, neuropathic, or mixed origin~* Patients with chronic non cancer pain~* Ongoing chronic opioid treatment with either oral morphine or oxycodone (long term - more than 3 months of at least a total daily opioid dose of 60 mg morphine or of 30 mg oxycodone)~* Pain of moderate intensity (\>4, on the numerical scale 0-10) despite ongoing opioid therapy\>~* Non-pregnant, non-lactating women~* Sufficient language skills to communicate with research staff~Exclusion Criteria:Non-ambulatory patients~* Clinically significant respiratory, renal, hepatic, or cardiac disease.~* Documented diagnosis of sleep apnea (the study physician may exclude patients who present with clinical features and complaints suggestive of a diagnosis of probable sleep apnea)~* History of illicit drug or alcohol dependence or abuse, abnormal drug taking / seeking behaviors~* Severe depression (\> 26 on the BDI)~* Patients who exhibit a score on the Mini Mental Status Exam (MMSE) of 26 or less. (The range of scores for mild dementia is 21-26 on the MMSE).~* Workman compensation, current or pending medical-legal litigation~* Hypersensitivity to study medication (oxymorphone)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- oxymorphone (Type: EXPERIMENTAL): participants switched to oxymorphone extended release (ER) via both oral and intravenous patient-controlled analgesia (IV-PCA) oxymorphone. After 24 hours, participants were discharged with oral oxymorphone ER and oxymorphone immediate release (IR) as needed

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features, with metastatic disease~* Castration-resistant prostate cancer (CRPC) demonstrated during continuous androgen deprivation therapy (ADT)/post orchiectomy~* Maintain castrate levels of testosterone (less than \[\<\] 50 nanogram per deciliter (ng/dL) \[1.72 nanomol per liter {nmol/L}\]) within 4 weeks before enrollment~* Prostate-specific antigen (PSA) evidence for progressive prostate cancer consists of a PSA level of at least greater than or equal to (\>=) 2 nanogram per milliliter (ng/mL) within 2 weeks before enrollment which has risen on at least 2 successive occasions, at least 1 week apart. If the confirmatory PSA value is less than the last PSA value, then an additional test for rising PSA will be required to document progression~* Participants who received a first generation anti-androgen \[for example, bicalutamide, flutamide, nilutamide (not approved in Japan)\] as part of an initial combined androgen blockade therapy or as second-line hormonal therapy must show continuing disease progression off the anti-androgen for at least 4 weeks prior to the first dose of study drug~Exclusion Criteria:~* History of, or current metastases in the brain or untreated spinal cord compression~* Participants with progressive epidural disease~* Participants has a history of another malignancy within 5 years before screening~* Prior treatment with second generation anti-androgens ( for example, enzalutamide) or Cytochrome P450 17 (CYP 17) inhibitors \[for example, abiraterone acetate, orteronel, galeterone, systemic ketoconazole (not approved in Japan, respectively)\]~* Participants had used radiopharmaceutical agents (for example, Strontium-89) or investigational immunotherapy (for example, sipuleucel-T) within 12 weeks before the first dose of study drug

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): Participants will receive 8 capsules of JNJ-56021927, 240 milligram (mg) as single oral dose on Day 1. After participants will receive daily JNJ-56021927, 240 mg on Day 1 of Cycle 1 until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever comes first.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Gadobutrol 1.0 Molar (Gadavist) in Patients for Central Nervous System (CNS) Imaging

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Is at least 18 years of age~* Is referred for a contrast-enhanced MRI of the CNS based on current clinical symptoms or results of a previous imaging procedure~* Has been fully informed about the study, including provisions of the Health Insurance Portability and Accountability Act (HIPAA) as applicable, and has consented to participate~Exclusion Criteria:~* Has any contraindication to the MRI examinations or the use of Gd-containing contrast agents~* Has a history of severe allergic or anaphylactoid reaction to any allergen including drugs and contrast agents~* Has severe cardiovascular disease (eg, known long QT syndrome, acute myocardial infarction \[\< 14 days\], unstable angina, congestive heart failure New York Heart Association class IV) or acute stroke (\< 48 hours)- Patients with acute renal insufficiency of any severity due to hepato-renal syndrome or in the perioperative liver transplantation period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Gadobutrol then Gadoteridol (Type: EXPERIMENTAL): Participants received a single dose of gadobutrol 0.1 mmol/kg body weight (bw) via i.v. (intravenous) in Period 1 and a single dose of gadoteridol at the approved dose, 0.1 mmol/kg bw, via i.v. in Period 2.
- Gadoteridol then Gadobutrol (Type: EXPERIMENTAL): Participants received a single dose of gadoteridol at the approved dose, 0.1 mmol/kg bw, via i.v. in Period 1 and a single dose of gadobutrol 0.1 mmol/kg bw via i.v. in Period 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Investigating the Postprandial Glucose Metabolism After Treatment With Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female aged 18-64 years (both inclusive) at the time of signing informed consent~* Subjects diagnosed (clinically) with type 1 diabetes mellitus at least 365 days prior to the day of screening~* Body mass index 18.5-28.0 kg/m\^2 (both inclusive)~Exclusion Criteria:~* Smoker (defined as a subject who is smoking at least five cigarettes or the equivalent per day) who is not able or willing to refrain from smoking or use of nicotine gum or transdermal nicotine patches during the inpatient period~* Subject who has donated any blood or plasma in the past month or more than 500 mL within 3 months prior to screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Faster aspart (Type: EXPERIMENTAL): None
- Insulin aspart (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Effectiveness and Safety of Paliperidone Extended-release (ER) Tablets in the Prevention of Recurrence in Adult Patients With Schizophrenia.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* DSM-IV diagnosis of schizophrenia at least 1 year before screening~* experiencing an acute schizophrenic episode with a total PANSS score between 70 and 120~* agree to be hospitalized for a minimum of 14 days at the start of the study~* capable of administering study medication themselves or have assistance with study medication administration consistently available throughout the study~* resided at the same address continuously for at least 30 days prior to screening~* able and willing to fill out self administered questionnaires~* washout of antiparkinsonian medications, beta-blockers~* antiepileptics, lithium 3 days prior to the start of the run-in phase~Exclusion Criteria:~* DSM-IV Axis I diagnosis other than schizophrenia~* DSM-IV diagnosis of substance dependence within 6 months prior to screening (nicotine and caffeine dependence are not exclusionary)~* preexisting severe gastrointestinal narrowing (pathologic or iatrogenic)~* injection of a depot antipsychotic within 120 days before screening, or use of paliperidone palmitate within 10 months before screening~* previous history of lack of response to risperidone when acutely psychotic~* history of neuroleptic malignant syndrome~* significant risk of suicidal or violent behavior

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes for at least 24 months~* BMI between 18 and 30 kg/m2~* Insulin naive subjects~* OAD treatment with max two OADs alone or combined with other therapy~* HbA1c between 7-12%~Exclusion Criteria:~* Type 1 diabetes~* Receipt of any investigational drug within the last three months prior to this trial~* Current or previous treatment with thiazolidiones within the last 6 months~* OAD treatment with three or more OADs within the last 4 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete